Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers.

Bridgewater J, Tabatabai G, Macarulla T, Stacchiotti S.

Open source

DOI
10.1016/j.ejcsup.2025.12.001
Published
2026-03-27
Container
EJC Suppl
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejcsup.2025.12.001,
  title = {Clinical advancement in the management of mutant isocitrate dehydrogenase (\<i\>IDH\</i\>) cancers.},
  author = {Bridgewater J and  Tabatabai G and  Macarulla T and  Stacchiotti S.},
  year = {2026},
  journal = {EJC Suppl},
  doi = {10.1016/j.ejcsup.2025.12.001},
  url = {https://doi.org/10.1016/j.ejcsup.2025.12.001}
}

RIS

TY  - JOUR
TI  - Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers.
AU  - Bridgewater J
AU  -  Tabatabai G
AU  -  Macarulla T
AU  -  Stacchiotti S.
PY  - 2026
JO  - EJC Suppl
DO  - 10.1016/j.ejcsup.2025.12.001
UR  - https://doi.org/10.1016/j.ejcsup.2025.12.001
ER  - 

APA

J, B., G, T., T, M., & S., S. (2026). Clinical advancement in the management of mutant isocitrate dehydrogenase (<i>IDH</i>) cancers.. EJC Suppl. https://doi.org/10.1016/j.ejcsup.2025.12.001

Source records